review quotes glp-1 π¨ Breaking out of the 5th Circuit: A major review is underway FDA issued 25 warning letters
Description
In the preexisting DR subgroup, the severity of diabetic retinopathy was similar between individuals with and without GLP-1 RA prescriptions at baseline after PSM (severe: 1537 [4.7%] vs 1569 [4.8%]
As such, GLP-1 receptor agonists have the potential to reinforce the concept of obesity as a treatable medical condition
The efficacy of IDegLira (Insulin Degludec/Liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial
Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes
Wegovy (semaglutide) drug details.
Obesity-induced and weight-loss-induced physiological factors affecting weight regain
